Anzeige
Mehr »
Mittwoch, 02.09.2026 - Börsentäglich über 12.000 News
Crypto.com-Deal ist fix! 22-Mio.-Firma sichert sich Zugang zu Billionen-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C6TD | ISIN: SE0016829824 | Ticker-Symbol: 5QO
Frankfurt
01.09.26 | 15:25
0,033 Euro
-1,81 % -0,001
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
QLUCORE AB Chart 1 Jahr
5-Tage-Chart
QLUCORE AB 5-Tage-Chart

Aktuelle News zur QLUCORE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
QLUCORE Aktie jetzt für 0€ handeln
26.08.Qlucore AB: Qlucore Signs Agreement with BioTuring Inc200Nasdaq First North-listed Qlucore, a leading provider of software for data analysis and precision diagnostics, today announced that it has entered into a reseller agreement with BioTuring, a pioneering...
► Artikel lesen
17.06.Qlucore AB: Qlucore Receives Approval for EUR 0.5 Million EU Payment1.018Qlucore, a leading provider of software for precision cancer diagnostics, has received approval for a third payment of approximately EUR 0.5 million under its previously awarded EU grant. The total...
► Artikel lesen
28.05.Qlucore AB: Year-end-report 1 May 2025 - 30 April 2026166AI-based tests for Acute Myeloid Leukemia and Bladder Cancer launched Fourth quarter, 1 February - 30 April 2026Net sales amounted to SEK 1,944k (3,461k).EBITDA adjusted amounted to SEK -2,516k (-2...
► Artikel lesen
13.04.Qlucore AB: Qlucore Launches AI-based test for Acute Myeloid Leukemia159Qlucore, listed on Nasdaq First North, announces the launch of a new Qlucore Insights test (Research Use Only) specifically developed for Acute Myeloid Leukemia (AML). The software-based test delivers...
► Artikel lesen
26.02.Qlucore AB: Interim report 1 May 2025 - 31 January 2026194New product release for protein data analysis launched Third quarter, 1 November 2025 - 31 January 2026Net sales amounted to SEK 2,190k (3,217k).EBITDA adjusted amounted to SEK -3,088k (-5,313k).Net...
► Artikel lesen
27.11.25Qlucore AB: Interim report 1 May - 31 October 2025295New share issue fully subscribed, reduced burn rate and additional customer buys Qlucore Diagnostics Second quarter, 1 August - 31 October 2025Net sales amounted to SEK 1,792k (1,855k).Operating result...
► Artikel lesen
27.11.25Qlucore AB: Disposal of intangible assets291Qlucore AB has decided to dispose of certain intangible assets of approximately SEK 19.5 million. The Board of Directors of Qlucore AB (publ) has, for precautionary reasons, decided to dispose of a...
► Artikel lesen
28.10.25Qlucore AB: Qlucore terminates liquidity guarantee agreement264Qlucore AB ("Qlucore") hereby announces that the company has terminated the agreement with Lago Kapital Oy regarding the assignment as liquidity guarantor. The purpose of the liquidity guarantor has...
► Artikel lesen
23.10.25Qlucore AB: Bulletin from the annual general meeting of Qlucore AB (publ)432The annual general meeting in Qlucore AB (publ) was held today, October 23, 2025, whereby the shareholders made the following decisions. Approval of the income statement and balance sheetThe annual...
► Artikel lesen
24.09.25Qlucore AB: Interim report 1 May - 31 July 2025240Funding secured First quarter, 1 May - 31 July 2025Net sales amounted to SEK 811k (1,675k).Operating result (EBIT) amounted to SEK -6,552 (-7,620k).Net result for the period amounted to SEK -6,619k...
► Artikel lesen
09.09.25New last trading day for paid subscription shares (BTA) of Qlucore AB289At the request of Qlucore AB, the last trading day in Qlucore AB's paid subscription shares will be changed from 2025-09-19 to 2025-09-11. Instrument: Paid subscription shares Short name: ...
► Artikel lesen
02.09.25The observation status for Qlucore AB (publ) is removed275On March 28, 2025, the shares in Qlucore AB (publ) (the "Company") were given observation status with reference to material adverse uncertainty in respect of the Company's financial position. Yesterday...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1